| Name | Title | Contact Details |
|---|
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to concentrate on high growth potential markets where there are visible, distinct needs recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use.
American Society of Pain Educators is a Montclair, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lumilife is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amedisys is a leading home health and hospice care company focused on bringing home the continuum of care. We deliver personalized home health and hospice care to thousands of patients and their families, in the comfort of their own homes. Our care teams deliver personalized home health and hospice care to approximately 380,000 patients each year. Amedisys is a post-acute care partner to more than 2,233 hospitals and 61,900 physicians across the country. We provide the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. Amedisys is a recognized innovator, being one of the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry`s first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient`s home health plan of care.